Eledon Pharmaceuticals (ELDN) Earnings Date, Estimates & Call Transcripts $5.30 +0.65 (+13.98%) (As of 11/1/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Eledon Pharmaceuticals Latest Earnings SummaryUpcoming Q3 Earnings DateNov. 14EstimatedActual EPS (Aug. 19) -$0.32 Missed By -$0.01 Consensus EPS (Aug. 19) -$0.31 Eledon Pharmaceuticals posted Q2 2024 earnings on August 19, 2024, reporting an EPS of -$0.32, which missed analysts' consensus estimates of -$0.31 by $0.01. With a trailing EPS of -$2.04, Eledon Pharmaceuticals' earnings are expected to grow next year, from ($1.52) to ($0.73) per share. ELDN Upcoming EarningsEledon Pharmaceuticals' next earnings date is estimated for Thursday, November 14, 2024, based off prior year's reporting schedules. Get Eledon Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataELDN Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ELDN Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Eledon Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.35-$0.33-$0.34Q2 20243-$0.36-$0.30-$0.33Q3 20243-$0.37-$0.20-$0.29Q4 20243-$0.38-$0.16-$0.28FY 202411($1.46)($0.99)($1.24) Eledon Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 11/14/2024(Estimated)------- 8/19/2024Q2 2024-$0.31-$0.32 -$0.01$0.42--5/9/2024Q1 2024-$0.37-$0.34+$0.03-$0.34-- 3/28/2024Q4 2023-$0.38-$0.29+$0.09-$0.29-- 11/9/2023Q3 2023-$0.41-$0.35+$0.06-$0.35-- 8/10/2023Q2 2023-$0.47-$0.40+$0.07-$0.40-- 5/11/2023Q1 2023-$0.71-$0.75 -$0.04-$0.75-- Get the Latest News and Ratings for ELDN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 3/30/2023Q4 2022-$0.70-$0.68+$0.02$2.73--11/14/2022Q3 2022-$0.68-$0.73 -$0.05-$0.73-- Eledon Pharmaceuticals Earnings - Frequently Asked Questions When is Eledon Pharmaceuticals's earnings date? Eledon Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 14th, 2024 based off last year's report dates. Learn more on ELDN's earnings history. Did Eledon Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Eledon Pharmaceuticals (NASDAQ:ELDN) missed the analysts' consensus estimate of ($0.31) by $0.01 with a reported earnings per share (EPS) of ($0.32). Learn more on analysts' earnings estimate vs. ELDN's actual earnings. How much profit does Eledon Pharmaceuticals generate each year? Eledon Pharmaceuticals (NASDAQ:ELDN) has a recorded net income of -$116.54 million. ELDN has generated -$2.04 earnings per share over the last four quarters. What is Eledon Pharmaceuticals's EPS forecast for next year? Eledon Pharmaceuticals's earnings are expected to grow from ($1.52) per share to ($0.73) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Corvus Pharmaceuticals Earnings Larimar Therapeutics Earnings Arcturus Therapeutics Earnings Verve Therapeutics Earnings Aquestive Therapeutics Earnings KalVista Pharmaceuticals Earnings SIGA Technologies Earnings Sage Therapeutics Earnings Valneva Earnings Xeris Biopharma Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for InvestorsTaiwan Semiconductor Soars on Earnings With More Room to RunBank of America Earnings Uncover Shifts in Consumer Spending Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). This page (NASDAQ:ELDN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
